KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) EBITDA Margin (2017 - 2025)

Historic EBITDA Margin for Sarepta Therapeutics (SRPT) over the last 12 years, with Q2 2025 value amounting to 32.21%.

  • Sarepta Therapeutics' EBITDA Margin rose 305200.0% to 32.21% in Q2 2025 from the same period last year, while for Jun 2025 it was 21.72%, marking a year-over-year increase of 185700.0%. This contributed to the annual value of 11.47% for FY2024, which is 543700.0% up from last year.
  • Sarepta Therapeutics' EBITDA Margin amounted to 32.21% in Q2 2025, which was up 305200.0% from 24.56% recorded in Q4 2024.
  • Over the past 5 years, Sarepta Therapeutics' EBITDA Margin peaked at 32.21% during Q2 2025, and registered a low of 203.36% during Q1 2023.
  • Moreover, its 5-year median value for EBITDA Margin was 25.43% (2021), whereas its average is 40.69%.
  • Per our database at Business Quant, Sarepta Therapeutics' EBITDA Margin crashed by -1534100bps in 2023 and then skyrocketed by 2117000bps in 2024.
  • Quarter analysis of 5 years shows Sarepta Therapeutics' EBITDA Margin stood at 60.55% in 2021, then surged by 31bps to 41.68% in 2022, then surged by 129bps to 11.9% in 2023, then soared by 106bps to 24.56% in 2024, then soared by 31bps to 32.21% in 2025.
  • Its EBITDA Margin stands at 32.21% for Q2 2025, versus 24.56% for Q4 2024 and 7.9% for Q3 2024.